Monday, November 29, 2021
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Accenture plc (ACN), Raytheon Technologies Corp. (RTX), and Becton, Dickinson and Co. (BDX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Accenture have outperformed the Zacks Consulting industry over the past year (+48.1% vs. +47.8%). The Zacks analyst believes that Accenture has been steadily gaining traction in its outsourcing as well as consulting businesses backed by high demand for services that can improve operating efficiencies and save costs.
Considering the growing need for cloud-based applications and software, Accenture’s investments in this space are likely to propel long-term growth. Stiff competition and pricing pressure, however, remain as the major headwinds. Higher talent costs due to a competitive talent market has also been hurting Accenture’s prospects.
(You can read the full research report on Accenture here >>>)
Raytheon shares have gained +18.7% in the year to date period against the Zacks Aerospace - Defense industry’s gain of +7.3%. The Zacks analyst believes that merger related synergies and solid order growth are likely to continue aiding Raytheon Technologies.
RTN’s management continues to expect both domestic and international program growth to remain robust for its defense business in the quarters ahead. The SEAKR Engineering acquisition is expected to boost this missile-maker’s space-based capabilities. Continued air travel restrictions due to the ongoing pandemic, however, continues to weigh on the operating results of RTN’s Aerospace business.
(You can read the full research report on Raytheon here >>>)
Shares of Becton, Dickinson have gained +1.6% in the past six months against the Zacks Dental Supplies industry’s gain of +2.4%, however, things seem to be improving for it. The Zacks analyst is encouraged by regulatory approvals, a plethora of launches as well as a slew of strategic acquisitions that the company has inked.
The FDA’s Emergency Use Authorization for Becton, Dickinson’s Veritor At-Home COVID-19 Test and the 510(k) clearance for expanded indications for Rotarex Rotational Excisional Atherectomy System, bode well for the long term. Stiff competition and persistent forex woes, however, remain as the major headwinds.
(You can read the full research report on Becton, Dickinson here >>>)
Other noteworthy reports we are featuring today include The Boeing Company (BA), Booking Holdings Inc. (BKNG) and Gilead Sciences, Inc. (GILD).
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Boeing Company (BA) : Free Stock Analysis Report
Accenture PLC (ACN) : Free Stock Analysis Report
Becton, Dickinson and Company (BDX) : Free Stock Analysis Report
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
Booking Holdings Inc. (BKNG) : Free Stock Analysis Report
Raytheon Technologies Corporation (RTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research